Table 1.
Strain | Intratracheal Administrated Bleomycin (Equivalent Unit, Supplier) | Survival Rate | Cause of Death | Role of Periostin | |
---|---|---|---|---|---|
Uchida et al.6 | BALB/c; WT (n=7) vs. KO (n=16) | 10 mg/kg (10 U/kg; Nippon Kayaku) | Less than 20% in WT; about 90% in KO (day 28) | Pulmonary fibrosis | Induction of inflammation |
Naik et al.8 | C57BL/6; periostin-neutralizing antibody (injected 10 and 15 days after bleomycin administration, n=10 each) | 0.05 unit per mouse (about 2 U/kg; Sigma) | 40% in control antibody; 100% in neutralizing antibody (day 19) | Pulmonary fibrosis | Fibrosis progression |
This study | C57BL/6; WT (n=17) vs. KO (n=31) | 2.5 U/kg (LKT Laboratories) | About 90% in WT; about 55% in KO (day 21) | Alveolar rupture | Increase in ECM stability |
WT and KO indicate the wild-type mice and the periostin-null mice, respectively. Abbreviation: ECM, extracellular matrix.